Stelo Glucose Biosensor

About Dexcom

Dexcom is a pioneering medical device company with a mission to empower people to take control of their health through innovative continuous glucose monitoring (CGM) technology. Founded in 1999, the company has achieved a dominant position in the diabetes care market with its best-in-class G7 systems and is now strategically expanding into the metabolic health space with its OTC Stelo biosensor. With a market cap of $24.44B, Dexcom's strategy leverages relentless product innovation, a robust payer coverage network, and a growing ecosystem of digital health partnerships to drive sustained growth.

Therapeutic Areas